BiotechTube

SHR0302 tablets、Placebo + SHR0302 tablets、Placebo + Placebo

Phase 3UNKNOWN
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Psoriatic Arthritis

Conditions

Psoriatic Arthritis

Trial Timeline

Aug 30, 2021 → Nov 13, 2024

NCT ID
NCT04957550

About SHR0302 tablets、Placebo + SHR0302 tablets、Placebo + Placebo

SHR0302 tablets、Placebo + SHR0302 tablets、Placebo + Placebo is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Psoriatic Arthritis. The current trial status is unknown. This product is registered under clinical trial identifier NCT04957550. Target conditions include Psoriatic Arthritis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT04957550Phase 3UNKNOWN

Competing Products

20 competing products in Psoriatic Arthritis

See all competitors
ProductCompanyStageHype Score
SonelokimabMoonLake ImmunotherapeuticsPhase 3
72
Sonelokimab + Placebo + AdalimumabMoonLake ImmunotherapeuticsPhase 2
47
Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
72
Sonelokimab + Placebo + RisankizumabMoonLake ImmunotherapeuticsPhase 3
72
Dose A VTX958 + Dose B VTX958 + PlaceboVentyx BiosciencesPhase 2
47
Ixekizumab + PlaceboEli LillyPhase 3
77
Ixekizumab + TirzepatideEli LillyPre-clinical
23
Ixekizumab + TirzepatideEli LillyPhase 3
77
Ixekizumab + AdalimumabEli LillyApproved
85
Alefacept + Methotrexate + PlaceboAstellas PharmaPhase 2
52
SUNPG18_07 I (Tildrakizumab 200 mg) + SUNPG18_07 II (Tildrakizumab 100 mg)Sun PharmaceuticalPhase 2/3
65
TILD sub-cutaneous (SC) injectionSun PharmaceuticalPhase 3
77
SUNPG1623 I + SUNPG1623 II + SUNPG1623 III + SUNPG1623 IV + PLACEBOSun PharmaceuticalPhase 2
52
TILD + matching placebo injectionsSun PharmaceuticalPhase 3
77
TILD + matching placebo injectionsSun PharmaceuticalPhase 3
77
Ixekizumab + AdalimumabEli LillyPhase 3
77
TirzepatideEli LillyApproved
85
Placebo + Ixekizumab 80 mg Q4W + Ixekizumab 80 mg Q2WEli LillyPhase 3
77
GuselkumabJohnson & JohnsonApproved
85
RSS0393 ointment + RSS0393 ointment + RSS0393 ointment placeboJiangsu Hengrui MedicinePhase 2
52

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85